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Abstract
HER-2/neu status of the primary breast cancer (PBC) is
determined by immunohistochemistry and fluorescent in situ
hybridization. Because of a variety of technical factors, however,
the PBC may not accurately reflect the metastatic tumor in terms of
HER-2/neu status. Recently published guidelines recommend that
tumors be defined as HER-2/neu positive if 30% or more of the
cells are 3+. Circulating levels of the HER-2 extracellular domain
can be measured in serum using a test cleared by the US Food
and Drug Administration, and increased serum HER-2/neu levels to
above 15 ng/ml can reflect tumor progression. Studies comparing
tissue HER-2/neu status of the PBC and HER-2/neu levels above
15 ng/ml in metastatic breast cancer patients are also reviewed.
Introduction
For many years estrogen receptor (ER) status has guided the
administration of hormone therapy to patients with breast
cancer. Positive ER status narrows the pool of patients
eligible for hormone therapy and increases the likelihood of
favorable response. However, ER status indicates that
approximately 50% of patients will respond, but it does not
predict which patients will respond to hormone therapy.
Similarly, the HER-2/neu status of breast carcinoma narrows
the pool of candidates eligible for HER-2/neu directed
therapies, but it does not definitively select those who will or
will not respond.
The HER-2/neu oncoprotein continues to be an important
target in the development of a variety of new cancer thera-
pies, which include mAb-based therapy, small-molecule drugs
directed at the internal tyrosine kinase portion of the HER-2/
neu oncoprotein, and vaccines. The most widely known HER-2/
neu-directed therapy is trastuzumab (Herceptin; Genentech,
South San Francisco, CA, USA). Trastuzumab is a humanized
recombinant mAb that specifically targets the HER-2/neu
extracellular domain (ECD). The effectiveness of trastuzumab
therapy has been proved not only in metastatic breast cancer
(MBC) patients [1] but also in early-stage breast cancer
patients receiving adjuvant trastuzumab therapy [2,3].
Recently, the US Food and Drug Administration (FDA)
approved lapatinib [4] (Tykerb, GSK, Philadelphia, PA, USA)
for clinical use. In addition, several tyrosine kinase inhibitors
are currently in clinical development, including HKI-272,
(Wyeth, Cambridge, MA, USA) [5] and AEE 788 (Novartis,
Hanover, NJ, USA) [6]. Therefore, accurate determination of
the HER-2/neu status is extremely important in guiding
therapy, and the reliability of the diagnostic method used to
determine HER-2/neu status is critical in selecting the most
appropriate patients for HER-2/neu directed therapies.
The present review is focused on HER-2/neu testing, and so
we address reports concerning the tissue tests used to
determine HER-2/neu status as well as tests to quantitate
circulating levels of the HER-2/neu ECD. Although there is
approximately 80% to 85% accuracy in determining HER-2/
neu status by tissue analysis, studies collectively show that
the HER-2/neu status of the primary breast cancer (PBC)
does not always accurately reflect the HER-2/neu status of
the MBC. We highlight some of the factors that contribute to
inaccurate assessment of HER-2/neu status by tissue testing,
in the hope that this will improve assessment of HER-2/neu
status. We also review reports on assays that have been
used to quantitate circulating levels of the HER-2/neu ECD,
and we present evidence that not all HER-2/neu assays have
been adequately validated, which has resulted in inaccurate
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data and uncertainty in the value of measuring the ECD of the
HER-2/neu oncoprotein. We describe studies that measure
the HER-2/neu ECD in the serum of MBC patients and
discuss evidence that increasing serum levels reflect tumor
progression whereas decreasing levels reflect response to
therapy or stable disease. We also review current thinking on
the potential clinical utility of measuring circulating ECD in
MBC and speculate on future applications.
Tissue methods used to determine HER-2/neu
status
Reports published during the past several years have
demonstrated that HER-2/neu tissue status can routinely be
assessed using two methods: immunohistochemistry (IHC),
which measures over-expression of the HER-2/neu full-length
oncoprotein (p185); and fluorescent in situ hybridization
(FISH), which measures the number of HER-2/neu gene
copies [7]. A third tissue method (not yet approved by the
FDA) that is growing in popularity is known as chromogenic
in situ hybridization (CISH) [8]. CISH also measures gene
amplification and has several technical advantages over
FISH. All three tissue tests are performed on breast cancer
tissue that has been formalin fixed and embedded in paraffin,
and findings are reviewed by trained pathologists to
determine HER-2/neu status.
There are two FDA-approved IHC tests for determining HER-2/
neu status: Herceptest (DAKO, Carpeteria, CA, USA), which
is a polyclonal antibody; and CB11 (Pathway, Ventana
Medical Systems, Tucson, AZ, USA), which is a mAb. Most
laboratories employing IHC generally use either Herceptest
or CB11 to measure the level of p185 expression on breast
cancer cells. To assess HER-2/neu status, a pathologist will
determine the percentage of tumor cells that stain with a 3+
intensity. In National Comprehensive Cancer Network
guidelines reported in 2006 by Carlson and coworkers [7], at
least 10% of tumor cells must stain 3+ by IHC for a patient to
be designated HER-2/neu positive. However, in a recent
2007 joint report from the American Society of Clinical
Oncology (ASCO) and the College of American Pathologists
(CAP), it was recommended that patients be considered
HER-2/neu positive only if more than 30% of the tumor cells
stain 3+ by IHC [9]. It is interesting to note, however, that
HER-2/neu positivity can depend on the antibody used to
assess HER-2/neu status. For instance, Fornier and
coworkers [10] reported that 95% of patients evaluated using
mAb CB11 were found to be 2+/3+, but in the same report
they found that 84% of patients evaluated using the polyclonal
Herceptest antibody were 2+/3+. Such variation in tissue
results has important implications for patients with tumors that
are potentially treatable with trastuzumab and chemotherapy.
The FISH method directly measures the number of HER-2/
neu genes, and when there is an increase in the number of
genes compared with normal it is referred to as ‘gene
amplification’. FISH testing results are semiquantitative and
are based on the average ratio of HER-2/neu signals to CEP
17 signals in nonoverlapping interphase nuclei of the lesion.
Three FISH tests are FDA-approved for selecting patients for
treatment with trastuzumab. The Path Vysion (Vysis Inc.,
Downers Grove, IL, USA) test requires a ratio (HER-2/neu to
CEP 17) of 2.0 or greater for the sample to be considered
amplified. The INFORM test (Ventana Medical Systems)
requires that at least 5.0 gene copies of HER-2/neu be present
if a sample is to be considered amplified. The third HER-2/neu
FISH test (DAKO) requires a ratio (HER-2/neu to CEN 17) of
at least 2.0 for a sample to be considered amplified.
Although IHC and FISH methods are strongly correlated to
histologic tissue, evaluation of tumor morphology by FISH is
difficult. However, the limitations of FISH were recently
improved upon by CISH. The latter technology visualizes the
amplification product along with morphologic features using a
peroxidase reaction, results can be viewed using a standard
light microscope, and CISH is cheaper and can be stored as
a permanent record. A majority of studies report concordance
between FISH and CISH of 83% to 100%, which is leading
to CISH gaining popularity in the research setting, but it is not
yet FDA approved for selecting patients for trastuzumab
therapy [7-9].
Variation in tests used to establish HER-2/
neu status
Despite considerable efforts devoted to standardizing
methods to determine HER-2/neu status by IHC or FISH,
there are still several conditions that result in false-positive or
false-negative results. Over the past few years numerous
reports have been published identifying discrepancies
between Herceptest and CB11, between IHC and FISH, and
between FISH and CISH, as well as discrepancies between
the various IHC and FISH methods from different manu-
facturers. Because all three tests use fixed tumor tissue, there
are several sources of potential error. For instance, the HER-2/
neu epitope can be destroyed by formalin fixation and many
years of storage. In many cases the primary tumor is removed,
formalin fixed, embedded in paraffin, and stored until the time
of recurrence. Therefore, antigen loss may occur in up to
20% of HER-2/neu positive samples. Several other condi-
tions can contribute to false-positive or false-negative IHC
results, including tissue processing, reagent variability, antigen
retrieval methods, scoring interpretation, tumor heterogeneity,
and the semiquantitative nature of the test [7-12].
Discrepancies in HER-2/neu status can be
laboratory dependent
In a 2006 report by Perez and coworkers [11], HER-2/neu
status determined by IHC and FISH were compared between
local pathology laboratories and central laboratories. A high
degree of discordance was found to exist between HER-2/
neu testing in the local laboratory and that in the central
laboratory. However, in cases of discordance between local
and central laboratories, there was a high degree ofPage 3 of 11
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agreement between the central laboratory and reference
laboratories. These results support the importance of using
high-volume experienced laboratories to determine HER-2/
neu status. Similarly, Reddy and coworkers [12] concluded
that use of high-volume HER-2/neu testing reference
laboratories will improve the process of selecting patients
who are likely to benefit from trastuzumab by accurate
determination of HER-2/neu status.
Comparison of HER-2/neu status: primary
tumor versus metastatic tumor
Currently, treatment of MBC patients with HER-2/neu
positive tumors is based on HER-2/neu status derived from
the primary tumor, which was generally removed many years
previously and stored as paraffin-embedded blocks. In a
2005 report by Zidan and coworkers [13] it was pointed out
that HER-2/neu status of the primary tumor may not
accurately reflect the HER-2/neu status of the metastatic
tumor, and that this should be taken into account when
making treatment decisions. Those investigators demon-
strated 14% discordance between primary and metastatic
tumors by IHC. Twelve per cent (7/58) of the patients were
HER-2/neu positive in the metastatic tumor yet negative in
the corresponding primary tumor. Interestingly, three of the
seven patients who were HER-2/neu negative in the primary
tumor but positive by IHC in the metastatic tumor responded
to trastuzumab-based therapy. The references list of that
report directed us to several other papers comparing HER-2/
neu status, as determined using IHC and FISH, between
primary breast tumor and metastatic tumor from the same
patient. Evidence supporting the observation that a primary
breast tumor can be HER-2/neu negative while the metastatic
tumor can positive is illustrated below with a few examples.
Edgerton and coworkers [14], employing IHC and FISH,
reported 20% discordance between the primary and
metastatic tumor, which was due to normal HER-2/neu
expression in the primary tumor and HER-2/neu over-
expression in the metastatic tumor. Gancberg and colleagues
[15] compared HER-2/neu status of the primary breast tumor
with that of at least one distant metastatic tumor in 107
patients using both IHC and FISH. There was a 6% (6/100)
rate of discordance with IHC between the primary and
metastatic tumor. In the six cases of discordance, there was
greater HER-2/neu staining in the metastatic tumor tissue
than in the primary tumor tissue. By FISH analysis, 7% (5/68)
of the cases were discordant. Three of the five discordant
patient specimens exhibited amplification in the metastatic
tumor but not in the primary tumor. It was also reported that if
all metastatic tumor sites were included in the analysis, then
the HER-2/neu positive metastatic tumors with a corres-
ponding negative primary tumor were more frequent than the
converse, suggesting that HER-2/neu expression in primary
tumors might represent an underestimation of reality. In
another study [16], 80 paired primary tumors and metastatic
tumors from the same patients were evaluated for HER-2/neu
expression using tissue tests. A change from HER-2/neu
negative status in the primary tumor to HER-2/neu positive
status in the metastatic tumor occurred in 17% of cases. In a
study conducted by Regitnig and coworkers [17] there was a
48% rate of discordance between primary and metastatic
tumor when 31 paired samples were evaluated by both IHC
and FISH. However, the 48% discordance rate included
changes from 0 to 1+ or 0 to 2+ by IHC; in four cases was
conversion to 3+ observed, yielding a discordance rate of
13.5%. In the 17 samples assessed by FISH, the discordance
rate was 25%.
Collectively, these reports strongly support the contention
that HER-2/neu status can be different between the primary
and metastatic tumor from the same patient when they are
evaluated using the standard tissue methods of IHC and
FISH. They provide evidence that there exists a population of
patients who are HER-2/neu negative in the primary tumor yet
HER-2/neu positive in the metastatic tumor sample. Although
this may be a small population of patients (in the 10% to 30%
range), it is clearly of concern that these patients may not be
eligible for trastuzumab therapy based on the initial tissue
test. The overall message from Zidan and coworkers [13] is
the recommendation that the discordance in tissue results be
taken into consideration when making treatment decisions.
Guidelines to define HER-2/neu positive status
A recent report by Carlson and coworkers [7] presents the
recommendations of a multidisciplinary panel of 24 experts
on how to determine HER-2/neu status accurately. According
to those recommendations, an IHC score of 0 or 1+, an
average HER-2/neu gene/chromosome 17 ratio of less than
1.8, or an average number of HER-2/neu gene copies/cell of
four or fewer (as determined by FISH) is considered to
represent HER-2/neu negative status. An IHC score of 3+, an
average HER-2/neu gene/chromosome 17 ratio of greater
than 2.2 by FISH, or an average number of HER-2/neu gene
copies/cell of six or more is considered to represent HER-2/
neu positive status. A tumor with an IHC score of 2+ should
be tested by FISH. Tumor samples with an average HER-2/
neu gene/chromosome ratio of 1.8 to 2.2, or an average
number of HER-2/neu gene copies/cell in the range from more
than four to fewer than six are considered to be borderline.
However, a 2007 report published in the Journal of Clinical
Oncology [9] provided guidelines from members of both
ASCO and CAP on improving the accuracy of HER-2/neu
testing in invasive breast cancer; the report also summarized
the utility of HER-2/neu as a predictive marker. This
publication also reported that approximately 20% of current
HER-2/neu tissue testing results may be inaccurate. The
authors concluded that when carefully validated tissue testing
is performed, the available data do not clearly demonstrate the
superiority of either IHC or in situ hybridization as a predictor
of benefit from anti-HER-2/neu therapy. Overall, the panel
recommended that HER-2/neu status be determined for all
Available online http://breast-cancer-research.com/content/9/3/207invasive breast cancer patients and that a testing algorithm
that relies on accurate, reproducible test performance,
including newly available tests such as CISH, be considered.
In these more recent recommendations, a positive HER-2/
neu result is defined as IHC staining of 3+ (uniform,
membrane staining) in more than 30% of invasive tumor cells.
A FISH result of more than six HER-2/neu gene copies per
nucleus or a FISH ratio of HER-2/neu gene signals to
chromosome 17 signals of more than 2.2 also indicate
HER-2/neu positivity. A negative result is an IHC staining of 0
or 1+, or a FISH result of fewer than four HER-2/neu gene
copies per nucleus, or FISH ratio of less than 1.8. Equivocal
results require additional action to arrive at a final
determination. It was recommended that, to perform HER-2/
neu testing, laboratories should demonstrate 95% concor-
dance with another validated test for positive and negative
assay values. The panel strongly recommended validation of
laboratory assay or modifications, use of standardized
operating procedures, and compliance with new testing
criteria, to be monitored with the use of stringent laboratory
accreditation standards, proficiency testing, and competency
assessment. The panel recommended that HER-2/neu testing
be done in a laboratory accredited by the CAP or in a
laboratory that meets the accreditation and proficiency
testing requirements set out by the document [9].
Circulating levels of HER-2/neu extracellular
domain in metastatic breast cancer patients
Many studies have established that the ECD of the p185
HER-2/neu is a p97-115kDa fragment that can be released
from normal or cancer cells and can be reproducibly and
accurately measured in serum using a test (for review, see
Carney and coworkers [18]) referred to as serum HER-2/neu.
The test was first cleared by the FDA in September 2000 on
an automated platform (Immuno-1) and in the microtiter plate
format (Siemens Medical Solutions Diagnostics, Tarrytown,
NY, USA). Studies have demonstrated a strong correlation
between the automated and the manual HER-2/neu tests
[19]. In 2003, the serum HER-2/neu test was also cleared for
use on another automated platform, namely the ADVIA
Centaur (Siemens Medical Solutions Diagnostics). The serum
HER-2/neu test is currently available in both a manual and an
automated platform (Siemens Medical Solutions Diagnostics)
[20]. In addition to the test receiving FDA clearance, a set of
high, medium, and low HER-2/neu controls to quality control
the assay and the results were also cleared by the FDA. It
should be noted that clearance by the FDA not only requires
a considerable amount of validation conducted in clinical
samples but it also requires documentation to prove
reproducibility of samples as well as the reproducibility in the
manufacture of multiple lots of reagents. This is often what is
missing in homebrew assays and those for research use only.
The HER-2/neu test cleared by the FDA is intended to
measure HER-2/neu ECD quantitatively in serum of women
with MBC. The use of the HER-2/neu test is indicated for
follow up and monitoring of patients with MBC whose initial
serum HER-2/neu value is above 15 ng/ml. HER-2/neu
values should be used in conjunction with information
available from clinical and other diagnostic procedures in the
management of MBC. The clinical utility of the serum
measurement of HER-2/neu as a prognostic indicator for
early recurrence and in the management of patients on
immunotherapy regimens has not been fully established. A
patient has an elevated serum HER-2/neu level if it is above
15 ng/ml. The upper limit of normal, defined as the lowest
concentration that exceeds 95% of the values for normal
healthy premenopausal and postmenopausal women, was
determined as part of the data submitted to the FDA. The
patient population included 121 serum samples from healthy
premenopausal women and a total of 120 serum samples
drawn from healthy postmenopausal women. In the
population of 241 healthy women, 95% of the serum HER-2/
neu values were found to be below 13.37 ng/ml. There was
no significant difference in the HER-2/neu values between
121 premenopausal and 120 postmenopausal women.
Based on this same population, the upper limit of normal was
defined as the mean plus two standard deviations, which was
14.78 ng/ml, and 15 ng/ml was defined as the normal cutoff
value. Any HER-2/neu values equal to or above 15 ng/ml are
considered elevated.
Since the introduction of this test as an in vitro diagnostic in
2000, many studies have monitored serum HER-2/neu levels
in serial samples of MBC patients; these show that increases
and decreases in serum HER-2/neu levels correlate with the
clinical course of disease [21-24]. For example, Cook and
coworkers [21] monitored 103 MBC patients who received
various regimens of hormonal or chemotherapy, and
demonstrated that changes in serum HER-2/neu levels
reflected changes in the clinical course of disease. There was
an 88.6% concordance between increasing levels of serum
HER-2/neu reflecting disease progression and decreasing
levels reflecting therapy response or stable disease.
Schippinger and colleagues [22] monitored serum HER-2/
neu levels in approximately 3,000 serum samples from 286
MBC patients receiving either hormone therapy or chemo-
therapy, or both. They showed that changes in serum HER-2/
neu levels paralleled the clinical course of disease. In addition,
they found that those patients in whom serum HER-2/neu
level was continuously elevated to above 15 ng/ml for the
entire course of disease had significantly worse overall survival
than did patients whose serum HER-2/neu levels were
continuously below 15 ng/ml. As part of the FDA clearance
procedure, it was found that a 20% difference from sample to
sample was necessary for the manual microtiter format,
whereas a 15% difference from point to point was necessary
to obtain statistically significant data [19,21].
An earlier review of the literature [18], which included the
vast majority of publications measuring HER-2/neu, showed
Breast Cancer Research    Vol 9 No 3 Carney et al.
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neu levels above the control population included in each
study. In contrast, 0% to 38% (mean 18.5%) of PBC patients
had HER-2/neu levels above those of the corresponding
control individuals. The wide range of serum HER-2/neu
values reported may be due to the lack of enzyme-linked
immunosorbent assay standardization that occurred in the
early days of HER-2/neu testing and before the FDA test
cleared 15 ng/ml as the cutpoint. Most of the early studies
measuring HER-2/neu levels in control individuals and
patients used research or homebrew assays without
standardization or diagnostically approved methods of valida-
tion. More recent reports using the FDA cleared test for
serum samples found a higher percentage of patients with
elevated HER-2/neu levels. Potential reasons for this are
described below.
Comparison of tests that measure the
circulating HER-2/neu extracellular domain
levels
It is important when measuring levels of any circulating
marker with clinical importance that strict assay development
guidelines be implemented and that the assay be well
validated and characterized from a quality point of view.
Before the decision by the FDA to clear the serum HER-2/
neu test with a standardized cutpoint of 15 ng/ml, many
reports used different research assays with various,
uncharacterized antibody specificities, calibrators, and cutoff
values to measure circulating HER-2/neu level. For instance,
in a previous review [18] it was shown that there were 21
references to the Triton-Ciba-Chiron HER-2/neu assay but
11 different cutoffs, ranging from 5 to 30 units/ml or from
120 or 450 fmol/ml. We found five references to the Nicherei
assay, three references to the Calbiochem or the Oncogene
Research Products assay, three references to the Dianova
assay, and two references to the Bender assay. We could not
find any references that described antibody specificities or
standardization of these assays, and neither were the findings
compared with standardized results. All of the assays
mentioned above were available for research use only, which
means that the performance characteristics of the assay had
not been determined. Unlike FDA-cleared in vitro diagnostic
products, there are no manufacturing guidelines for research
use only products, which often results in inconsistent findings.
The Bender assay was claimed to measure circulating soluble
p185, but there has never been been a scientific report of a
circulating full-length p185 and neither does the manu-
facturer present data to support the claim. It has clearly been
shown that the circulating fragment is a p97-115kDa, and so
it is unclear what the manufacturer meant by ‘circulating
soluble p185’.
In a study published in 1998 [25], using a homebrew HER-2/
neu assay and mAb 4D5 as the capture reagent, it was
reported that 259 out of 443 (58%) patient sera did not have
measurable circulating HER-2/neu levels. In contrast, reports
using the FDA-cleared serum HER-2/neu test reported that
all individuals tested, both normal (male and female) and
cancer patients, had some level of circulating serum HER-2/
neu. In a 1999 report [26], using the same enzyme-linked
immunosorbent assay based on mAb 4D5, baseline serum
concentrations of the circulating HER-2/neu were below the
detectable concentration in 73 out of 191 patients (38%).
The article concluded that no significant correlation could be
demonstrated between shed HER-2/neu concentrations and
patient response status. However, the conclusions were
based on data from a nonvalidated immunoassay with no
standardization, and no references demonstrating the
specificity of the research assay were presented. However,
an explanation for these results can be derived from a report
by Wong and Mass [27] presented at the ASCO 2000
annual meeting. In the report they compared the homebrew
mAb 4D5 assay with the FDA-cleared test. The poster
compared serum samples from the same MBC patients using
both the mAb 4D5-based assay and the FDA-cleared assay.
The authors concluded that the mAb 4D5 assay was not as
sensitive as the FDA-cleared assay, which helps explain the
results reported by the above-cited studies as well as other
studies using the homebrew mAb 4D5 assay [25,26].
In a similar abstract published in 2004 at the annual ASCO
meeting [28], Leyland-Jones and coworkers reported on a
study in which they measured HER-2/neu levels in 366
cancer patients, again using the homebrew mAb 4D5 assay.
Included was a combination of stage 2 and stage 3 breast
cancer patients and patients with non-small-cell lung
carcinoma (NSCLC). In the study it was concluded that no
obvious relationship existed between baseline HER-2/neu
levels and patient response, and in all cases the levels
dropped with antiproliferative therapy. Of the 366 patients
included in the 2004 poster, 103 patients were from the
NSCLC study. Combining breast cancer and NSCLC with
stage 2 and 3 cancer studies does not seem appropriate in
light of the FDA cleared indication for patients with MBC.
Despite the abstract and poster presented in 2000 by Wong
and coworkers [27] showing that the 4D5 assay had less
analytical sensitivity than the FDA-cleared assay, the authors
of the 2004 ASCO poster used the homebrew 4D5 assay.
In addition, the FDA assay is cleared for monitoring patients
with values above 15 ng/ml. In the 2004 poster by Leyland-
Jones and coworkers [28], conclusions were also based on
plotting values below 15 ng/ml. To date, these data have not
been published in a peer-reviewed journal.
In summary the homebrew, mAb 4D5 assay is not indicated
for use in NSCLC patients or for measuring serial values
below 15 ng/ml. Given the nature of the mAb 4D5, being a
homebrew assay, and therefore the potential for high
coefficients of variation, it is questionable whether differences
in values below 15 ng/ml are accurate or statistically
Available online http://breast-cancer-research.com/content/9/3/207
Page 5 of 11
(page number not for citation purposes)significant. Therefore, the findings and conclusions reported
in the articles cited [25-27] that used a nonstandardized and
unvalidated assay, which has been shown to be less sensitive
than the FDA-cleared test, should be viewed with caution,
especially in light of the numerous reports employing the
FDA-cleared serum HER-2/neu assay and the reproducible
finding of a 15 ng/ml cutoff.
Trastuzumab-treated metastatic breast
cancer patients and serum HER-2/neu levels
Schondorf and coworkers [23] and Esteva and colleagues
[24] evaluated patients with MBC who were treated with
trastuzumab-based therapies (trastuzumab plus various
combinations of chemotherapy); these patients were found to
exhibit serial changes in serum HER-2/neu levels that
correlated with clinical course of disease. In addition, reports
by Köstler and coworkers [29] and Esteva and colleagues
[30] illustrated that changes in serum HER-2/neu level
paralleled the clinical course of disease, and in some cases
changes in serum HER-2/neu levels preceded changes in
clinical course of disease. Collectively, studies in which
patients were treated with hormone therapy, chemotherapy,
or trastuzumab/chemotherapy indicate that serial changes in
serum HER-2/neu levels paralleled changes in the clinical
course of disease [20-24].
The report by Köstler and coworkers [29] also demonstrated
that a significant decrease in serum HER-2/neu level from the
pretreatment baseline to 30 days after treatment was an early
predictor of outcome with trastuzumab therapy. Subsequent
reports from Esteva [30], Fornier [10], and Tse [31] and their
colleagues supported the observation that a significant
decrease in serum HER-2/neu from pretreatment level to 30
days after treatment was a predictor of outcome to
trastuzumab therapy.
Because these earlier reports found different cutoff levels, Ali
and coworkers [32] coordinated a multicenter/multinational
study of 307 MBC patients that monitored changes in serum
HER-2/neu levels during trastuzumab-based therapies. The
data were presented at the 2006 San Antonio Breast Cancer
Conference in abstract form. Serum HER-2/neu levels at
baseline were compared with serum HER-2/neu levels from
blood drawn at a median of 30 days after trastuzumab
initiation. Patients who did not achieve a greater than 20%
decline in serum HER-2/neu levels had a lower response rate,
shorter duration of response, shorter time to progression, and
decreased overall survival compared with those patients who
did achieve a decline of more than 20%. A report by
Kashiwaha and coworkers [33] presented as a poster at the
2006 San Antonio Breast Cancer Conference also supported
that a decline in serum HER-2/neu level by 20% predicts
outcome with trastuzumab-based therapies. However, the
number of patients included in the study was not defined.
These observations may be clinically useful in stratifying
patients with a lower probability of optimal response to
trastuzumab and chemotherapy, and therefore these findings
may be exploited to identify candidates for additional HER-
2/neu-directed therapies such as the tyrosine kinase
inhibitors [4-6].
Monitoring metastatic breast cancer patients
receiving lapatinib
Lapatinib (Tykerb, GSK, Philadelphia, PA, USA) is an oral
dual tyrosine kinase inhibitor that targets HER-2/neu and
epidermal growth factor receptor positive tumors in MBC. It
was recently approved by the FDA for use in combination
with capecitabine for the treatment of patients with advanced
breast cancer or MBC whose tumors over-express HER-2
and who have received prior therapy with an anthracycline, a
taxane, and trastuzumab.
At the 2004 ASCO meeting, Blackwell and coworkers [34]
reported that a decrease in serum HER-2/neu levels at 4 and
8 weeks after initiation of lapatinib correlated with response
to therapy and was an early indicator of clinical response.
Additional studies are currently being evaluated to confirm
these findings.
Serum HER-2/neu levels and clinical
outcome
Some studies have suggested that clinical outcomes can be
improved by maintaining serum HER-2/neu levels below
15 ng/ml. For instance, Schippinger and coworkers [22]
reported results in 286 MBC patients; they found that those
individuals with continuously elevated (>15 ng/ml) serum
HER-2/neu levels had a significantly poorer survival after
disease recurrence than did patients with HER-2/neu levels
continuously or temporarily below 15 ng/ml. A decrease in
elevated serum HER-2/neu levels to under 15 ng/ml or levels
continuously below 15 ng/ml during the course of disease
correlated with significantly longer survival. In a 2005 report
by Lipton and coworkers [35], it was shown that an increase
in serum HER-2/neu level to above 15 ng/ml at the time of
disease progression on first-line hormone therapy correlated
with significantly shortened survival. The median survival from
initiation of therapy was 47.8 months for patients whose
serum HER-2/neu level was continuously below 15 ng/ml. In
those patients who exhibited an increase in serum HER-2/
neu at the time of disease progression, the median survival
was 26.5 months. The survival of patients in whom serum
HER-2/neu level changed from under 15 ng/ml to greater
than 15 ng/ml did not differ significantly from the survival of
patients whose serum HER-2/neu level was above 15 ng/ml
from the start of therapy (median 20.8 months). Survival from
the time of disease progression was longest (28.1 months)
for those patients whose serum HER-2/neu level remained
under 15 ng/ml, and it was shortest (12.5 months) for those
patients whose serum HER-2/neu level remained elevated to
above 15 ng/ml. However, patients whose serum HER-2/neu
level changed from below 15 ng/ml to above 15 ng/ml had a
median survival of 15.2 months.
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it was found that patients who had a serum HER-2/neu level
continuously below 15 ng/ml had an overall survival of more
than 1,000 days, whereas those patients whose serum HER-2/
neu level was continuously above 15 ng/ml had an overall
survival of only 618 days. In patients who started therapy with
a serum HER-2/neu level above 15 ng/ml but which declined
to below 15 ng/ml during therapy, the overall survival was in
excess of 1,000 days and similar to that in the patients whose
serum HER-2/neu level remained below 15 ng/ml.
Pretreatment serum HER-2/neu levels
associated with poor response to therapies
In 1989 Wright and coworkers [36] reported that HER-2/neu
over-expression, based on IHC, was associated with a
reduced rate of response to first-line hormone therapy in
MBC patients. Since then, several studies [37-39] have
demonstrated that elevated pretreatment serum HER-2/neu
levels are associated with a significantly lower rate of
response to endocrine therapy. In a first-line hormone therapy
trial reported by Lipton and coworkers [39], MBC patients
with elevated pretreatment serum HER-2/neu levels had a
shorter duration of response, shorter time to progression, and
shorter overall survival than did patients with serum HER-2/
neu levels below 15 ng/ml. Sandri and coworkers [40]
reported that increased pretreatment serum HER-2/neu
identified those patients with more aggressive tumors and
lesser response to chemotherapy. In addition, Colomer and
colleagues [41] found that pretreatment serum HER-2/neu
levels correlated significantly with rate of response to
chemotherapy. Patients with pretreatment levels higher than
normal were less responsive than were patients with serum
HER-2/neu less than normal. Several other reports (for
review, see Carney and coworkers [18]) have shown that
elevated pretreatment serum HER-2/neu levels are
associated with poor clinical outcomes.
Serum HER-2/neu levels in metastatic breast
cancer and HER-2/neu positivity by tissue tests
In several reports, HER-2/neu tissue positivity of the primary
tumor was compared with serum HER-2/neu levels in the
same patients with MBC. In a 2001 study reported by Harris
and coworkers [42], strong concordance was identified
between IHC/FISH results for the primary tumor and elevated
serum levels in the same patients with MBC. Similar findings
were reported by Tse and coworkers [43], Mouller and
colleagues [44], and, more recently, by Kong and coworkers
[45]. The latter group found a strong correlation between
serum HER-2/neu levels in patients with MBC and the IHC
and FISH findings for the primary tumor. They showed that
the HER-2/neu tissue negative group had a median serum
HER-2/neu level of 22.2 ng/ml, whereas the tissue positive
group had a mean serum HER-2/neu level of 363 ng/ml. In
one study [44], some patients who were HER-2/neu negative
by tissue tests had very high serum HER-2/neu levels with
the emergence of MBC.
In a multicenter, phase III randomized trial conducted by the
Breast Cancer International Research Group (BCIRG; study
007) [46], docetaxel and trastuzumab (TH) was compared
with docetaxel, platinum salt (cisplatin or carboplatin), and
trastuzumab (TCH) as first-line chemotherapy in women with
MBC. Women enrolled in the study were required to have
primary breast tumors with HER-2/neu amplification, as
determined by centralized FISH analysis. At the time of
recurrence, a baseline serum HER-2/neu level was measured.
The goal was to determine the percentage of patients with
HER-2/neu amplification who had elevated (>15 ng/ml)
baseline serum HER-2/neu before initiation of trastuzumab-
based therapy. Baseline was considered to be the last
available determination within 21 days before first treatment.
The median baseline serum HER-2/neu level for all patients at
the time of recurrence (n = 123) was 75.8 ng/ml (range 8 to
3,280 ng/ml), with no statistically significant difference
between patients randomly assigned to receive TH (n = 64;
median 65.9 ng/ml) and those randomized to receive TCH
(n = 59; median 89.9 ng/ml). Overall, 89.5% of the 123
patients with HER-2/neu amplified primary tumors had serum
HER-2/neu levels above 15 ng/ml at the time of metastatic
disease (86% in TH versus 92% in TCH).
Many previous reports have identified an approximately 80%
to 90% correlation between tissue HER-2/neu positivity and
elevated serum HER-2/neu levels at the time of MBC.
However, not all reports are in agreement. For instance,
Hoopmann and coworkers [47] reported 40% of 20 HER-2/
neu 3+ patients had elevated serum HER-2/neu. Also,
Bethune-Volters and colleagues [48] found that only 55% of
the 33 patients who were IHC 3+ or FISH amplified had
elevated serum HER-2/neu levels. However, based on
previously published data and the controlled 007 BCIRG
study [46], patients with HER-2/neu tissue positivity in the
primary tumor might be excellent candidates for monitoring
for increasing serum HER-2/neu levels after surgery as a
means of detecting early breast cancer recurrence. However,
such an indication has not been cleared by the FDA.
Frequency of elevated serum HER-2/neu
levels in breast cancer patients
To appreciate the frequency with which elevated serum
HER-2/neu levels are identified in patients with breast
cancer, we reviewed papers that reported serum HER-2/neu
levels in patients that were above control levels. In the 2004
report published in Clinical Chemistry [18] a total of 60
studies, representing 7,639 breast cancer patients, were
reviewed. In the 25 studies representing 2,622 patients with
PBC, approximately 18.1% had elevated serum HER-2/neu
levels. However, it should be noted that these figures were
derived from all HER-2/neu reports, regardless of whether the
assay was validated. However, Manouni and coworkers [49]
recently demonstrated a 28.2% incidence of elevated serum
HER-2 in patients with PBC receiving neoadjuvant therapy. In
contrast, however, one report [50] found that only 6% of 128
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possible that PBC patients with elevated serum HER-2/neu
levels have more extensive disease than understood.
In 50 publications representing 5,044 patients with MBC, we
found (on average) that 48.6% (range 23% to 80%) had
elevated serum HER-2/neu levels. In more than 40% of the
reports, it was found that 50% or more of the MBC patients
had elevated serum HER-2/neu levels [16]. Several recent
papers [18,51-53] reported that 50% to 60% of MBC
patients had an elevated serum HER-2/neu. This difference
may have several explanations, such as differing patient
populations or wider use of the standardized FDA cleared
serum HER-2/neu test. It also may be that some reports
employ hormone receptor-positive patients only whereas
others include mixed populations. These data are in sharp
contrast to the many publications indicating that only 20% to
30% of patients with PBC have HER-2/neu over-expression
by IHC or FISH amplification. It also raises the possibility that
HER-2/neu status can change, by whatever mechanism, from
PBC to the MBC setting.
Comparison of HER-2/neu status in primary
breast tumor and serum HER-2/neu level in
metastatic breast carcinoma
In a search of the literature, we also found numerous
publications that demonstrated the existence of a population
of women with PBC who were designated HER-2/neu
negative by tissue testing but who developed serum HER-2/
neu levels above 15 ng/ml in MBC (for review, see the report
by Carney and coworkers [18]). For example, Andersen and
coworkers [54] found that 28 of the 82 patients (34%) who
had IHC negative PBC developed elevated serum HER-2/
neu levels during MBC. Fehm and colleagues [53] also found
that 34% of patients designated HER-2/neu negative by
tissue testing had elevated serum HER-2/neu levels at the
time of MBC.
The observation that a population of patients with a HER-2/neu
negative primary tumor can develop elevated serum levels at
MBC is consistent with the report by Zidan and coworkers
[13]. Those investigators demonstrated the presence of a
population of patients in whom HER-2/neu status was negative
in the primary tumor but with HER-2/neu tissue positivity in the
metastatic tumor. This also raises the question of whether
circulating serum HER-2/neu can be used as a surrogate
marker for the presence of a HER-2/neu positive tumor.
HER-2/neu is more than just another tumor
marker
Several reports suggest that serum HER-2/neu levels are
associated with tumor burden, HER-2/neu over-expression,
and receptor activation. Molina and coworkers [55] showed
that cleavage of the ECD leads to increased phosphorylation
of the intracellular tyrosine kinase. This observation suggests
that circulating HER-2/neu level not only is a marker of tumor
over-expression but also is indicative of the degree of
receptor activation.
Ali and coworkers [56] and Fehm and colleagues [53]
examined the question of whether serum HER-2/neu reflects
tumor aggressiveness or is simply a surrogate marker of
disease bulk. In the report by Ali and coworkers [56] pre-
treatment samples from 566 MBC patients were tested for
serum HER-2/neu levels as well as for levels of CA15-3, a
surrogate marker of tumor burden. They concluded that
serum HER-2/neu is a significant independent predictive and
prognostic factor in hormone receptor positive MBC patients,
even when adjusted for tumor burden using CA15-3. In
addition, Fehm and colleagues [53], using a multivariate
analysis, also concluded that when serum HER-2/neu results
were adjusted for tumor load with CA15-3, serum HER-2/neu
remained an independent marker of tumor aggressiveness
and reflected the biologic behavior of the tumor. Several
other studies have also concluded that the combination of
serum HER-2/neu and CA15-3 identifies a subset of patients
with a worse prognosis when compared with one marker
alone. However, it has also been reported on several
occasions that there is a weak correlation between serum
HER-2/neu and CA 15-3, but each provides important
information about the biology of the tumor.
Monitoring serum HER-2/neu for detection of
early recurrence
Several reports have shown that monitoring serum HER-2/
neu levels after surgery in patients with HER-2/neu positive
tissue may be beneficial in that it may permit earlier detection
of breast cancer recurrence. In a report by Pichon and
coworkers [57], serum HER-2/neu levels were measured
before first metastasis in 128 out of 701 breast cancer
patients, and 45% of these women had elevated serum
HER-2/neu. In recurrent breast cancer, elevated serum
HER-2/neu levels may permit early detection of occult
metastasis and identification of patients with a high
probability of shortened survival. This study also showed that
elevated serum HER-2/neu levels before first metastasis were
indicative of aggressive disease.
Fehm and colleagues [53] found that 27% of breast cancer
patients with recurrence had elevated serum HER-2/neu
levels 6 months before clinical signs or clinical diagnosis. This
percentage increased to 50% of the patients who had
elevated serum HER-2/neu levels at 3 months before clinical
diagnosis. Isola and coworkers [58] reported that 37% of
patients could be predicted to have recurrent breast cancer
on the basis of increasing serum HER-2/neu levels 6 months
before the actual clinical diagnosis.
Overall, a search of the literature found approximately 12
publications that reported an increase in serum HER-2/neu
levels that could be measured 2 to 9 months before the
actual clinical diagnosis of recurrent breast cancer [59].
Breast Cancer Research    Vol 9 No 3 Carney et al.
Page 8 of 11
(page number not for citation purposes)Monitoring serum HER-2/neu levels in all HER-2/neu tissue
positive patients might be a way to detect breast cancer
recurrence earlier.
Conclusion
HER-2/neu status is important information that is needed to
guide therapy in patients with HER-2/neu positive breast
cancer; therefore, accurate determination of HER-2/neu
status by IHC or FISH is essential to providing appropriate
treatment. Many studies now demonstrate that the HER-2/
neu status of the primary tumor may not accurately reflect the
HER-2/neu status of patients receiving trastuzumab therapy
in either adjuvant or metastatic setting. Therefore, one
potential clinical use for the serum HER-2/neu test is to
identify patients with an elevated serum HER-2/neu test but a
negative HER-2/neu tissue test. This could be a reason to re-
evaluate the original tumor or a metastatic tumor by IHC and
FISH for HER-2/neu positivity. Serum HER-2/neu is a test
that should complement tissue testing, but it should not be
used in place of IHC or FISH. However, use of the serum
HER-2/neu test is not approved for selecting patients for
trastuzumab therapy. No clinical studies have been performed
to determine how patients with elevated serum levels will
respond to trastuzumab.
Because most IHC and FISH studies report 20% to 30%
HER-2/neu positivity in PBC, and several studies now show a
20% false-negative rate in primary breast tumors, a 50%
proportion of MBC patients with elevated serum HER-2/neu
is certainly a possibility. It is also possible, in light of the
BCIRG 007 data [46], that recent reports in which the FDA-
cleared assay indicated that 50% to 60% of MBC patients
can have elevated serum levels are real. Variations in this
percentage observed over the years has been confused by
the use of nonstandardized assays as well as studies that
included patients with stage 2 or 3 breast cancer, such as
the study conducted by Leyland-Jones and coworkers [28].
The most probable reason for a patient to be found to be
HER-2/neu negative, however, is that the patient’s tumor has
less than the 10% 3+ positive cells required to be
designated HER-2/neu positive. However, it is also likely that
there are enough HER-2/neu positive cells in the primary
tumor (regardless of cutoff) to generate a HER-2/neu positive
metastatic breast cancer. Whatever the percentage of
HER-2/neu positive cells is in the primary breast tumor, they
could be the tumor cells with the biologic growth advantage
and those most likely to migrate to distant sites and create
metastatic tumors. However, based on recent recommen-
dations by ASCO and CAP that more than 30% of cells be
HER-2/neu 3+ by IHC for a patient to be considered HER-2/
neu positive, this should decrease of the rate of false-negative
tissue results.
Several studies conducted during the past few years also
support that as many as 50% to 60% of unselected MBC
patients can have elevated serum HER-2/neu levels.
However, the frequency of serum HER-2/neu elevation is
higher in MBC patients selected for primary tumor HER-2/
neu positivity, as recently demonstrated by the BCIRG 007
study [46]. That study showed that 89.5% of MBC patients
identified as HER-2/neu positive in the primary tumor by FISH
amplification had elevated serum HER-2/neu levels
(>15 ng/ml).
It is also possible that serum HER-2/neu testing could have
clinical value in managing patients who specifically have
HER-2/neu positive tumors. Studies are starting to emerge
that show that the patients with the better clinical outcomes
have HER-2/neu levels that are continuously below 15 ng/ml
[22,32,34]. In trastuzumab-treated patients, studies also
show that a drop of less than 20% in serum HER-2/neu level
from pretreatment to post-treatment is associated with poor
clinical outcome, as compared with those patients with a
drop greater than 20%. Those patients who do not achieve a
20% decline might benefit from additional HER-2/neu
inhibitors that are currently in clinical development. Clearly,
these observations are exciting, and additional studies are
needed to determine whether serum HER-2/neu can have
clinical value in HER-2/neu positive patients and in patients
receiving HER-2/neu directed therapies such as Tykerb.
With the emergence of many targeted therapies, it will be
increasingly important that new mechanism-based circulating
biomarkers, such as HER-2/neu, epidermal growth factor
receptor, and vascular endothelial growth factor, be used in
the metastatic cancer setting to monitor the efficacy of the
targeted therapies and to select patients for targeted
therapies. The goal of new diagnostic tests should be to use
mechanism-based biomarkers, such as serum HER-2/neu, to
routinely monitor patients from the time of first diagnosis and
tumor removal in order to detect early breast cancer recur-
rence, with the intention being to institute therapeutic inter-
vention earlier and hopefully to increase overall survival.
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